InsiderSignal.AI

InsiderSignal.ai

TARS - Tarsus Pharmaceuticals, Inc.

Insider Sale by Neervannan Seshadri (COO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

6 days ago, Neervannan Seshadri, serving as COO at Tarsus Pharmaceuticals, Inc. (TARS), sold 11,324 shares at $68.21 per share, for a total transaction value of $772,444.00. Following this transaction, Neervannan Seshadri now holds 86,255 shares of TARS.

This sale represents a 12.00% decrease in Neervannan Seshadri's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, March 17, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, March 19, 2026, 2 days after the trade was made.

Tarsus Pharmaceuticals, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Neervannan Seshadri

Neervannan Seshadri

COO

Neervannan Seshadri, Ph.D. is the Chief Operating Officer of Tarsus Pharmaceuticals, Inc. (TARS), a position he has held since July 2020.[[1]](https://fintool.com/app/research/companies/TARS/people/seshadri-neervannan)[[2]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tars/tarsus-pharmaceuticals/management) Aged 56 as of April 2025, he oversees operations, including the successful launch and commercial ramp of XDEMVY, contributing to net product sales growth from $14.7 million in 2023 to $180.1 million in 2024.[[1]](https://fintool.com/app/research/companies/TARS/people/seshadri-neervannan) His 2024 compensation was approximately US$3.19 million, with ownership of 0.17% of the company's shares valued at $5.3 million.[[2]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tars/tarsus-pharmaceuticals/management) Seshadri holds a B.S. in Pharmacy (with Honors) from BITS Pilani and a Ph.D. (with Honors) in Pharmaceutical Chemistry from the University of Kansas.[[1]](https://fintool.com/app/research/companies/TARS/people/seshadri-neervannan) His career highlights include Senior Vice President of Global Pharmaceutical Development at Allergan, Inc. (2015–2020), Vice President of Pharmaceutical Development at Allergan (2007–2015), Director of Pharmaceutics R&D at Amgen Inc. (1999–2007), and Senior Research Investigator at Bristol-Myers Squibb (1994–1999).[[1]](https://fintool.com/app/research/companies/TARS/people/seshadri-neervannan) He also serves on the board of Iolyx Therapeutics since 2020.[[1]](https://fintool.com/app/research/companies/TARS/people/seshadri-neervannan) Recently, on March 5, 2026, he received equity grants of 27,310 stock options and 17,161 RSUs, vesting from 2027 to 2030.[[4]](https://www.stocktitan.net/sec-filings/TARS/form-4-tarsus-pharmaceuticals-inc-insider-trading-activity-041c5f37ef2e.html)

View full insider profile →

Trade Price

$68.21

Quantity

11,324

Total Value

$772,444.00

Shares Owned

86,255

Trade Date

Tuesday, March 17, 2026

6 days ago

SEC Filing Date

Thursday, March 19, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Tarsus Pharmaceuticals, Inc.

Company Overview

No company information available
View news mentioning TARS

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4923554

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime